Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
- Study conducted in the United-States aims to consolidate leucocyte GAG and skin GAG content measurement as disease biomarkers in MPS VI children and adults
- These two new biomarkers will be used to assess the efficacy of odiparcil in reducing GAG levels
- Study results are expected in the first half of 2020
- In parallel, the Phase IIa clinical study evaluating odiparcil in MPS VI is progressing and headline results are now expected by the end of the year for all treatment arms
Daix (France), September 2, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the recruitment of the first patients in a new biomarker study in children and adults with mucopolysaccharidosis type VI (MPS VI)
Conducted at the UCSF Benioff Children’s Hospital in Oakland, California, by Dr Paul R. Harmatz, the trial will investigate leukocyte glycosaminoglycan (leukoGAGs) levels in three children and skin glycosaminoglycan (skinGAGs) levels in three adults with MPS VI before and post enzyme replacement therapy (ERT), and in six age-matched control subjects not affected by MPS VI. This study is part of Inventiva’s strategy to develop biomarkers to evaluate the efficacy of odiparcil, the Company’s drug candidate for the treatment of MPS, in reducing leukoGAGs and skinGAGS. This approach has been launched following the Food and Drug Administration’s (FDA) guidance on the relevance of biomarkers for diseases such as MPS1. Results of this study are expected in the first half of 2020.
A first biomarker study sponsored by Inventiva showed that, despite ERT treatment, the current standard of care, leukoGAG levels remained very high and were not impacted when measured one hour after ERT infusion although the activity of the arylsulfatase B2 enzyme was very high. This finding suggests that leukoGAG levels may be further reduced with a new treatment such as odiparcil.
Measurement of leukoGAGs and skinGAGs is performed in the ongoing Phase IIa iMProveS (improve MPS treatment) clinical study evaluating odiparcil for the treatment of MPS VI patients. Given the recent progress achieved in the iMproveS study, headline results for all treatment arms are now expected by the end of the year. Inventiva had initially planned to publish the study results in two steps: the headline results of the double-blind placebo controlled arms by the end of the year followed by the results of the open label cohort during Q1 2020.
Dr. Paul R. Harmatz, the principal investigator of this new biomarker study , said: “I am very excited about the launch of this second biomarker study with the recruitment of the first patients. Following our first biomarker study that demonstrated the limitations of ERT in reducing leukoGAGs, this trial will help us better understand the dynamic of the response to this therapy in leukocytes. It could also possibly provide a second measure of GAG storage in a readily accessible tissue such as the skin, thereby strengthening the appraisal of intracellular GAG variations.”
Odiparcil is an orally-available small molecule that acts on the underlying cause of the symptoms of mucopolysaccharidosis (“MPS”), a group of rare, progressive genetic disorders. MPS is characterized by the accumulation of glycosaminoglycans (“GAGs”), polysaccharides which are important for the modulation of cell‑to‑cell signaling and the maintenance of tissue structure and function, in the lysosomes of cells. Due to genetic mutations, lysosomes in patients with MPS contain deficient versions of the enzymes necessary to break down GAGs. As a result, GAGs accumulate within the lysosomes, causing the latter to swell and interfere with the ordinary functioning of cells, leading to the symptoms associated with MPS. MPS is categorized by subtypes, depending on the enzyme that is deficient and the corresponding GAGs that accumulate. By modifying how GAGs are synthesized, odiparcil facilitates the production of soluble GAGs that can be excreted in the urine, rather than accumulating in cells. Specifically, odiparcil acts on chondroitin sulfate (“CS”) and dermatan sulfate (“DS”), either or both of which accumulate in patients with MPS I, II, IVa, VI and VII.
Inventiva is currently evaluating odiparcil in a Phase IIa clinical trial for the treatment of adult patients with the subtype MPS VI.
Odiparcil has been granted Orphan Drug Designation (ODD) for the treatment of MPS VI by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and has also obtained Rare Pediatric Disease Designation (RPDD) in the U.S. for the treatment of MPS VI.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates – lanifibranor and odiparcil – in non-alcoholic steatohepatitis (“NASH”) and mucopolysaccharidosis (“MPS”), respectively, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease. Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of this disease for which there are currently no approved therapies.
Inventiva is also developing odiparcil, a second clinical‑stage asset, for the treatment of patients with MPS, a group of rare genetic disorders. The Company is currently investigating odiparcil in a Phase IIa clinical trial for the treatment of patients with the MPS VI subtype.
In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. The Company has established two strategic partnerships with AbbVie and Boehringer Ingelheim in the areas of autoimmune diseases and idiopathic pulmonary fibrosis (“IPF”) respectively. AbbVie has started the clinical development phase of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. Both collaborations entitle Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the partnerships.
The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology a well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, around 60% of which are proprietary, as well as a wholly‑owned research and development facility.
Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). www.inventivapharma.com
Chairman & CEO
+33 3 80 44 75 00
Yannick Tetzlaff / Tristan Roquet Montegon
+33 1 53 96 83 83
email@example.com +1 212 915 3820
The information stated above was prepared by Inventiva and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Inventiva, or any of its products, by The Regents of the University of California, its officers, agents and employees.
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence" filed with the Autorité des Marchés Financiers on April 12, 2019 under n° R.19-006 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.
1 Slowly progressive, low-prevalence rare diseases with substrate deposition that results from single enzyme defects: providing evidence of effectiveness for replacement or corrective therapies; Guidance for Industry; U.S. Department of Health and Human Services Food and Drug Administration; July 2018.
2 Arylsulfatase B is the enzyme that naturally degrades GAGs within the body and which is deficient in MPS VI patients.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Banks net position in the Riksbank17.9.2019 16:42:00 CEST | Press release
SEP 17, 2019 SEK MILLION LENDING BORROWING 348
Vostok Emerging Finance invests into Xerpa, Brazil’s leading HR platform and salary-on-demand provider.17.9.2019 15:00:00 CEST | Press release
Stockholm, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vostok Emerging Finance (“VEF”) announces its USD 8.5 mln investment into leading Brazilian HR platform and salary-on-demand provider, Xerpa. VEF led a broader Series B investment round of USD 13 mln and is joined by Founders Fund (the first institutional investor in Facebook and SpaceX) led by Peter Thiel, one of the founders of PayPal, alongside existing investors, Kaszek Ventures, Redpoint e.ventures and QED. Post the transaction VEF holds a minority stake and board representation in the company. Xerpa’s salary-on-demand product, Xerpay, allows employees to access their already earned wages, instantly and at any time, similar to Wagestream in the UK. Brazil has long suffered from some of the highest interest rates globally, poor financial inclusion and 60% of workers struggle to make their paycheck last the month. Through Xerpay, employees gain instant financial security and thus can avoid the cumulative spiral of debt, defaults and pena
Vostok Emerging Finance investerar i Xerpa, brasiliens ledande HR-plattform och löneutjämningsprodukt.17.9.2019 15:00:00 CEST | Pressemelding
Stockholm, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Vostok Emerging Finance (“VEF”) meddelade idag att bolaget har investerat 8.5 MUSD i Xerpa, brasiliens ledande HR-plattform och leverantör av Xerpay, bolagets löneutjämningsprodukt. VEF ledde Serie B-finansieringsrundan om totalt 13 MUSD, i vilken även Founders Fund (den första institutionella investeraren i Facebook and SpaceX) ledd av Peter Thiel, en av PayPals grundare, deltog tillsammans med de befintliga investerarna Kaszek Ventures, Redpoint e.ventures och QED. Genom denna investering äger VEF en minoritetspost och har styrelserepresentation i bolaget. Xerpa’s löneutjämningsprodukt, Xerpay, ger löntagare åtkomst till sin redan intjänade lön, omgående och vid vilken tidpunkt som helst, likt Wafestream i Storbritannien. Brasilien har länge lidit av några av världens högsta räntor, låg andel finansiellt inkluderade individer och 60% av arbetstagarna kämpar för att få lönen att räcka månaden ut. Genom Xerpay får löntagare omedelbar finans
Prosafe SE: Mandatory notification of trade17.9.2019 14:38:00 CEST | Press release
Jesper K. Andresen, Chief Executive Officer, has on 17 September 2019 purchased 51,591 shares in Prosafe SE at an average price of NOK 9.602 per share. Following the transaction, Jesper K. Andresen owns 84,067 shares in Prosafe SE. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The Company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 17 September 2019 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig H. Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Sampo plc: Managers’ Transactions (Martinsen)17.9.2019 14:35:00 CEST | Press release
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:35 pm Sampo plc: Managers’ Transactions (Martinsen) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with terms and conditions of the long-term incentive scheme 2014. ____________________________________________ Person subject to the notification requirement Name: Martinsen, Ivar Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: INITIAL NOTIFICATION Reference number: 743700UF3RL386WIDA22_20190917122147_10 ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume: 1,770 Unit price: 38.1824 EUR Aggregated transactions (1): Volume: 1,770 Volume weighted average price: 38.1824 EU
Sampo plc: Managers’ Transactions (Lapveteläinen)17.9.2019 14:35:00 CEST | Press release
SAMPO PLC MANAGERS’ TRANSACTIONS 17 September 2019 at 3:35 pm Sampo plc: Managers’ Transactions (Lapveteläinen) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with terms and conditions of the long-term incentive scheme 2014. ____________________________________________ Person subject to the notification requirement Name: Lapveteläinen, Patrick Position: Other senior manager Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: INITIAL NOTIFICATION Reference number: 743700UF3RL386WIDA22_20190917130819_9 ____________________________________________ Transaction date: 2019-09-13 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume: 2,253 Unit price: 38.1824 EUR Aggregated transactions (1): Volume: 2,253 Volume weighted average price: